

---

**Gestational diabetes, but not pre-pregnancy overweight predicts cardio-metabolic markers in offspring twenty years later**

Nina Kaseva, Marja Vääräsmäki, Jouko Sundvall, Hanna-Maria Matinoli, Marika Sipola, Marjaana Tikanmäki, Kati Heinonen, Aulikki Lano, Karoliina Wehkalampi, Dieter Wolke, Aimo Ruokonen, Sture Andersson, Marjo-Riitta Järvelin, Katri Räikkönen, Johan G Eriksson, Eero Kajantie

*The Journal of Clinical Endocrinology & Metabolism*  
Endocrine Society

Submitted: December 19, 2018

Accepted: February 25, 2019

First Online: March 05, 2019

---

Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance and before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Advance Article manuscripts and the final, typeset articles. The manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Advance Article page.

---

DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express or particular purpose, or non-infringement. Changes will be made to these manuscripts before publication. Review and/or use or reliance on these materials is at the discretion and risk of the reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising references to, products or publications do not imply endorsement of that product or publication.

GDM affects offspring cardio-metabolic markers

**Gestational diabetes, but not pre-pregnancy overweight predicts cardio-metabolic markers in offspring twenty years later**

Nina Kaseva<sup>1</sup>, Marja Väärasmäki<sup>1,2</sup>, Jouko Sundvall<sup>1</sup>, Hanna-Maria Matinoli<sup>1,3</sup>, Marika Sipola<sup>1,2,4</sup>, Marjaana Tikanmäki<sup>1,4</sup>, Kati Heinonen<sup>5</sup>, Aulikki Lano<sup>6</sup>, Karoliina Wehkalampi<sup>6</sup>, Dieter Wolke<sup>7</sup>, Aimo Ruokonen<sup>8,9</sup>, Sture Andersson<sup>6</sup>, Marjo-Riitta Järvelin<sup>10,11,12,13,14</sup>, Katri Räikkönen<sup>5</sup>, Johan G Eriksson<sup>1,15,16</sup>, Eero Kajantie<sup>1,2,6,17</sup>

<sup>1</sup>National Institute for Health and Welfare, Helsinki and Oulu, Finland. <sup>2</sup>PEDEGO Research Unit (Research Unit for Pediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynecology), Medical Research Center Oulu (MRC Oulu), Oulu University Hospital and University of Oulu, Oulu, Finland. <sup>3</sup>Department of Nursing Science, University of Turku, Turku, Finland. <sup>4</sup>Institute of Health Sciences, University of Oulu, Oulu, Finland.

<sup>5</sup>Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland. <sup>6</sup>Children's Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

<sup>7</sup>Department of Psychology, University of Warwick, Warwick, United Kingdom. <sup>8</sup>NordLab Oulu, Oulu University Hospital, Oulu, Finland. <sup>9</sup>Department of Clinical Chemistry, University of Oulu, Oulu, Finland.

<sup>10</sup>Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment & Health, School of Public Health, Imperial College London, London, UK. <sup>11</sup>Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland. <sup>12</sup>Biocenter Oulu, University of Oulu, Oulu, Finland. <sup>13</sup>Unit of Primary Care, Oulu University Hospital, Oulu, Finland. <sup>14</sup>Department of Life Sciences, College of Health and Life Sciences, Brunel University London, Kingston Lane, Uxbridge, Middlesex UB8 3PH, United Kingdom. <sup>15</sup>Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. <sup>16</sup>Folkhälsan Research Center, Helsinki, Finland. <sup>17</sup>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

**ORCID numbers:**

0000-0003-4648-0022

Kaseva

Nina

Received 19 December 2018. Accepted 25 February 2019.

**Context:**

Maternal gestational diabetes (GDM) and pre-pregnancy overweight/obesity (body mass index, BMI  $\geq 25\text{kg/m}^2$ ) may adversely affect offspring cardio-metabolic health.

**Objective:**

To assess associations of maternal GDM and pre-pregnancy overweight/obesity with adult offspring cardio-metabolic risk factors.

**Design:**

Longitudinal cohort study (ESTER and AYLS).

**Setting:**

Province of Uusimaa and Northern Finland.

**Participants:**

At mean age 24.1 years (SD 1.3), we classified offspring to offspring of mothers with 1) GDM regardless of pre-pregnancy BMI (OGDM; n=193), 2) normoglycemic mothers with

pre-pregnancy overweight/obesity (ONO, n=157) and 3) normoglycemic mothers with pre-pregnancy BMI < 25 kg/m<sup>2</sup> (controls, n=556).

#### Main Outcome Measures:

We assessed cardio-metabolic biomarkers from blood and measured resting blood pressure and heart rate.

#### Results:

Compared with controls, OGDM and ONO had higher fasting glucose [1.6% (95% confidence interval 0.1, 3.1)]; [2.3% (0.5, 4.3), respectively]; and insulin [12.7% (4.4, 21.9)]; [8.7% (0.2, 17.8)]. These differences attenuated to non-significance when adjusted for confounders and/or current offspring characteristics including BMI or body fat percentage. OGDM showed lower sex hormone binding globulin [SHBG; men: -12.4% (-20.2, -3.9), women: -33.2% (-46.3, -16.8)], high-density lipoprotein [-6.6% (-10.9, -2.2)] and apolipoprotein A1 [-4.5% (-7.5, -1.4)], these differences survived the aforementioned adjustments. Heart rate and other biomarkers were similar between groups.

#### Conclusions:

Adult offspring of mothers with GDM have increased markers of insulin resistance and a more atherogenic lipid profile; these are only partly explained by confounders or current offspring adiposity. Maternal pre-pregnancy overweight/obesity is associated with impaired offspring glucose regulation, which is explained by confounders and/or current adiposity.

We measured cardio-metabolic markers in offspring of mothers with GDM, pre-pregnancy overweight and controls. GDM was, unlike maternal overweight, linked with an unhealthier cardio-metabolic profile.

## Introduction

Metabolic abnormalities, including alterations in lipid and carbohydrate metabolism, are likely among women with gestational diabetes (GDM), overweight (body mass index, BMI  $\geq$  25 kg/m<sup>2</sup>) or obesity (BMI  $\geq$  30 kg/m<sup>2</sup>) during pregnancy. At a critical period of fetal development, exposure to e.g. hyperglycemia, may induce long-term impacts on the fetus by creating a metabolic memory, previously described as fetal programming (1). Prenatal exposure to a hyperglycemic environment is known to alter growth trajectories and homeostatic regulatory mechanisms, and these changes predispose offspring to epigenetic changes (2, 3). It is likely that both maternal GDM and overweight/obesity provide a prenatal environment making the fetus susceptible to adverse in utero programming. This may cause increased risk of next-generation overweight and obesity, and result in an intergenerational cycle of obesity and insulin resistance.

Offspring of mothers with GDM show markers of insulin resistance and metabolic syndrome, higher BMI and waist circumference by adolescence (4). Further, adult offspring of mothers with GDM represent a risk group for overweight and metabolic syndrome (5).

Exposure to maternal obesity during pregnancy also affects offspring health, particularly with increased risk for obesity and metabolic sequelae (6). In a recent review by Nicholas et al. maternal obesity increased offspring risk of both obesity and insulin resistance in childhood, adolescence and adulthood (7). Previous studies have also linked high maternal pre-pregnancy BMI to unfavorable offspring body composition in infancy (8), childhood (9), adolescence (10) and young adulthood (11). Even at a mean age of 62 years a less favorable

body composition and higher BMI in the offspring has been reported (12). However, it is not always clear to what extent the associations represent genetic or lifestyle factors, shared by the family, and to what extent they represent causal programming effects. Moreover, it is uncertain to what extent these offspring consequences are a result of exposure to maternal GDM and to what extent maternal overweight/obesity.

Despite previously well-established data on the strong influence of maternal pre-pregnancy overweight/obesity or GDM on offspring's increased risk for obesity and metabolic sequelae during childhood, it is less clear whether the effects extend into adult age.

Taking these observations together, we hypothesized that maternal GDM and pre-pregnancy overweight/obesity may affect cardio-metabolic risk factors in adult offspring. In this study, we investigate the impact of exposure to maternal GDM or pre-pregnancy overweight/obesity on adult offspring cardio-metabolic health.

## Materials and Methods

### Participants

Participants of the current study come from two prospective birth cohorts (Figure 1) (11): the ESTER Maternal Pregnancy Disorders Study and the Arvo Ylppö Longitudinal Study (AYLS).

The ESTER Study consists of two arms (Figure 1): 1) ESTER Preterm Birth (13) and 2) ESTER Maternal Pregnancy Disorders arms. The present study is based on the latter arm. All ESTER study participants were born in the two northernmost provinces of Finland. Those born in 1985–1986 were recruited from the Northern Finland Birth Cohort 1986 (NFBC 1986) (14) and those born in 1987–1989 through the Finnish Medical Birth Register (FMBR) (13), as previously described (15). We selected all participants of the ESTER Maternal Pregnancy Disorders arm who were confirmed to have maternal GDM ( $n=157$ ), regardless of the mother's pre-pregnancy BMI. Among ESTER clinical study participants invited as controls (15), participants were stratified into two groups: one group with maternal pre-pregnancy overweight/obesity included offspring born at term to mothers with pre-pregnancy BMI  $\geq 25\text{kg/m}^2$  and no GDM ( $n=44$ ), while the control group constituted the remaining controls, all with maternal pre-pregnancy BMI  $< 25\text{kg/m}^2$  and no GDM ( $n=281$ ).

All AYLS participants (Figure 1) were born in the province of Uusimaa, in Southern Finland between 1985 and 1986. This cohort consists of all live-born infants admitted to neonatal wards in obstetric units, or transferred to the neonatal intensive care unit of the Children's Hospital, Helsinki University Central Hospital within 10 days of their birth, with the population ranging from severely ill preterm infants to infants born at term, requiring only brief inpatient observation, and their controls, as previously described (16, 17). Of these AYLS cohort participants, with data available, we selected 1) all who were exposed to maternal GDM, at any maternal BMI ( $n=37$ ), 2) those who had maternal BMI  $\geq 25\text{kg/m}^2$  and no GDM ( $n=109$ ) and 3) controls (i.e. originally recruited as controls, maternal BMI  $< 25\text{kg/m}^2$  and no GDM;  $n=266$ ).

For all study participants, perinatal data were collected from healthcare records and questionnaires. Length of gestation, maternal GDM, hypertension (gestational or chronic) and preeclampsia (including superimposed) diagnoses were independently confirmed according to prevailing criteria by reviewing original hospital records (4, 18). Maternal GDM was

screened for and diagnosed by oral glucose tolerance test (OGTT). Screening was performed in the maternal welfare clinics between 26 and 28 gestational weeks. Indications for screening were glucosuria, prior GDM, suspected fetal macrosomia, previous macrosomic infant (birth weight >4,500 g), maternal pre-pregnancy BMI  $\geq 25$  kg/m<sup>2</sup>, and maternal age  $\geq 40$  years. The OGTT was performed after overnight fasting by using a 75-g oral glucose load. At the time of diagnosis in the 1980s, the following cutoff limits for GDM were used for venous blood glucose: >5.5 mmol/l at fasting, >11.0 mmol/l and >8.0 mmol/l, 1 hour and 2 hours after the glucose load, respectively. According to prevailing national guidelines, a diagnosis of GDM required a minimum of one abnormal value in the OGTT (4). For comparison, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) Consensus Panel diagnostic criteria used today are set at fasting plasma glucose  $\geq 5.1$  mmol/l, and  $\geq 10.0$  mmol/l and  $\geq 8.5$  mmol/l following a 75g oral glucose load (19).

Offspring to mothers with type 1 (n=28) or 2 diabetes (n=1) were excluded from all analyses. We further excluded subjects who were pregnant (n=9) during the clinical examination, reported having cerebral palsy (n=8), mental disability (n=11) or severe physical disability (n=5), as these conditions might affect the measured outcomes. We categorized all ESTER and AYLS cohort participants who underwent biochemical measures into three groups: 1) offspring of mothers with GDM (OGDM) at any level of maternal BMI, 2) offspring of normoglycemic mothers with pre-pregnancy overweight/obesity (ONO) and 3) controls, i.e. offspring of mothers with pre-pregnancy BMI < 25kg/m<sup>2</sup> and no GDM. As a result, 906 subjects were included in the analyses; OGDM n = 193, ONO n= 157 and 556 controls.

### **Ethics**

Our study protocol was in accordance with the Declaration of Helsinki. It was approved by the Ethics Committees of the University of Oulu, the Helsinki City Maternity Hospital, the Helsinki University Central Hospital and Jorvi Hospital, the Ethics Committee of the Northern Ostrobothnia Hospital District and the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District. Written informed consent was obtained from all participants. Because of individual participant consent, these data are not freely available. Researchers requesting data access are asked to contact the corresponding author. Requests may be subject to ethics review and/or participant's re-consent.

### **Measures and procedures**

Anthropometry was measured during clinical examinations conducted in 2009-2011 for ESTER participants and during 2009-2012 for AYLS participants. Height was measured three times without socks and shoes, with a portable stadiometer. Weight was measured during the clinical visit. Most of our participants also underwent bioimpedance measurement and the bioimpedance device (InBody 3.0, Biospace Co., Ltd., Seoul, Korea) contains a scale. For individuals who did not undergo bioimpedance we used an electronic scale. BMI was calculated using means of the repeated measurements [weight (kg) / height squared (m<sup>2</sup>)].

All participants attended a clinical visit in the morning, after an overnight fast. They were examined by a trained study nurse. After a 5-minute rest in a sitting position, blood pressure was measured 3 times from the right upper arm using an automatic oscillometric blood pressure monitor (Omron M10-IT Intellisense, Omron Healthcare Co., Kyoto, Japan). All participants completed questionnaires regarding both participant and parental health status,

including medical history and medications. Data on highest parental educational attainment were enquired and categorized into four levels (dummy coded) to serve as an indicator of childhood socioeconomic status.

### Laboratory analyses

At the clinical visit venous blood samples were taken in a sitting position with a light stasis into a fluoride-citrate tube (Venosafe, Terumo Europa, Leuven, Belgium) for glucose assays and into a tube containing clot activator (Venosafe) for other assays. Fluoride-citrate plasma and serum were separated by centrifuging, frozen locally immediately after separation, and then transported frozen on dry ice to the biochemistry laboratory of the Genomics and Biomarker Unit (former the Disease Risk Unit) at National Institute for Health and Welfare (Helsinki, Finland) and the Oulu University Hospital laboratory. All analyses were performed on a clinical chemistry analyzer (Architect ci8200 Abbott Laboratories, Abbott Park, Illinois, USA) at the biochemistry laboratory in the AYLS and ESTER studies, except for fasting plasma glucose, total cholesterol (TC), high- and low-density lipoprotein cholesterol (HDL-C and LDL-C), triglycerides (TGs), alanine aminotransferase (ALT), aspartate transaminase (AST), gamma glutamate (GT) and uric acid regarding ESTER study participants. In the ESTER study these samples were analyzed by using an Advia 2400 automatic chemical analyzer (Siemens Diagnostics, Terrytown, NY, USA) at Oulu University Hospital laboratory, and have been described in detail previously (13) (freely available as web appendix).

For standardizing measurements, the biochemistry laboratory has taken part in Lipid Standardization Program organized by Centers for Disease Control and Prevention (CDC, Atlanta, Georgia, USA) and External Quality Assessment Schemes organized by Labquality (Helsinki, Finland). During the course of the studies, the between-assay coefficient of variation (CV%, mean  $\pm$ SD), systematic error (Bias%, mean  $\pm$ SD) and the principle of the methods in the biochemistry laboratory are shown in Supplementary Table 1 (20).

### Statistical analyses

All statistical analyses were conducted with IBM SPSS Statistics versions 24 and 25 (SPSS Inc., Chicago, IL, USA). Analyses were performed in a combined dataset of both birth cohorts (ESTER and AYLS). We compared descriptive characteristics between participants with *t*-test (continuous variables) and  $\chi^2$ -test (categorical variables). The significance level was set to two-tailed  $P < 0.05$ . As the biochemical measures were not normally distributed, we log-transformed them prior to statistical analyses, to attain normality. We used multiple linear regression models to compare cardio-metabolic biochemical measures, blood pressure and heart rate between adult offspring of mothers with GDM or pre-pregnancy overweight/obesity with controls. We adjusted for age, sex and birth cohort in model 1. Prenatal and parental confounders were taken into account in model 2, as we additionally adjusted for gestational age, birth weight SD score, maternal hypertension or preeclampsia during pregnancy, maternal smoking during pregnancy, parental educational attainment, parental history of hypertension, diabetes, stroke or myocardial infarction. Participant related factors, including age, sex, birth cohort, BMI, height and daily smoking were adjusted for in model 3. Finally, in the full model 4, all the above mentioned covariates were included.

## Results

Perinatal and current characteristics and parental medical history of the OGDM, ONO and control groups are presented in Table 1. For comparison, these data are also shown separately for the two source cohorts in Supplementary Table 2 (20). Mean age of offspring at assessment was 24.1 years (SD 1.3) and 51.3 % were women. Among offspring, 2 OGDM, 2 ONO and 8 controls were born from twin pregnancies, the remainder were all singletons. As a sensitivity analysis, we excluded all twins and reran all analyses. This did not affect our results. Cardio-metabolic biochemical measures, heart rate and blood pressure of the offspring, with corresponding reference or target values are presented in Table 2.

### **Cardio-metabolic markers in offspring of mothers with gestational diabetes (Table 3)**

There were clear associations between maternal GDM and adult offspring cardio-metabolic markers. Fasting glucose and insulin were higher in OGDM compared with controls, although adjusting for confounders and current offspring characteristics including BMI attenuated these differences to non-significance (Table 3, Supplementary Table 3) (20). Further, OGDM had lower sex hormone binding globulin (SHBG) in both OGDM-men and OGDM-women. Also HDL-C, Lipoprotein (a) (Lp(a)) and Apolipoprotein A1 (ApoA1) were lower; apart from Lp(a), these differences survived adjustment for confounders and current characteristics. No statistically significant differences were seen in heart rate, testosterone, LDL-C, TGs, Apolipoprotein B (ApoB), free fatty acid (FFA), uric acid or liver tests (ALT, AST, GT). In model 1, TC and blood pressure was similar between OGDM and controls, while after adjusting for confounders and current characteristics TC, systolic and diastolic blood pressures were slightly lower in OGDM (Table 3, Supplementary Table 3) (20).

We further reran all analyses, replacing BMI and height with lean body mass and fat percentage in models 3 and 4 (data not shown). The results remained similar for model 3. In model 4, our findings of lower FFA [-9.2% ((-17.6, -0.1)] and hsCRP [-23.2 (-40.3, -1.1)] in OGDM both reached statistical significance.

To further distinguish between effects of maternal GDM and maternal overweight/obesity on adult offspring cardiovascular risk factors, we reran all analyses separately comparing offspring to mothers with 1) GDM and pre-pregnancy BMI < 25kg/m<sup>2</sup> (n=115) 2) GDM and pre-pregnancy BMI ≥ 25kg/m<sup>2</sup> (n=71) with controls (n=556). Most of our results remained similar (Supplementary Table 4) (20). A combination of maternal GDM and overweight/obesity showed a greater effect on fasting glucose and insulin than maternal overweight/obesity alone. Adjusting for confounders attenuated these differences between groups and this was largely due to offspring BMI as a mediator in OGDM with maternal BMI ≥ 25 kg/m<sup>2</sup>.

### **Cardio-metabolic markers in offspring of mothers with overweight/obesity (Table 3)**

Associations found between maternal pre-pregnancy overweight/obesity and adult offspring cardio-metabolic markers were mostly explained by current offspring characteristics and confounders. Fasting glucose and insulin were both higher in ONO vs. controls, these findings disappeared after adjustments in models 2-4 (Table 3, Supplementary Table 3) (20). In men, serum testosterone was lower in model 1, also this difference attenuated after adjustments in models 2-4. All other cardio-metabolic markers, including heart rate, SHBG, FFA, TC, HDL-C, LDL-C, TGs, Lp(a), ApoA1, ApoB, liver tests and uric acid were similar between ONO and controls. Only in model 2, hsCRP was higher in the ONO group, adjustment for confounders diluted this finding. However, although systolic blood pressure

was not different between groups in model 1, it was somewhat lower in models 2-4 in ONO-participants (Table 3, Supplementary Table 3) (20).

As with OGDM, we also reran all analyses comparing ONO vs. controls, replacing BMI and height with lean body mass and fat percentage in models 3 and 4. No changes were seen in the results (data not shown).

We further reran all analyses separately comparing offspring to mothers with pre-pregnancy BMI  $\geq 30\text{kg/m}^2$  (n=28) vs. controls. Most results remained similar (data not shown). However, in model 1, hsCRP [66.2% (95% CI: 3.6, 166.3)], TGs [21.5% (95% CI: 2.3, 44.3)] and ApoB [10.8% (95% CI: 0.1, 22.7)] were all higher in offspring exposed to maternal pre-pregnancy obesity compared with controls. Further, in model 1, heart rate was lower [-5.5% (95% CI: -10.0, -1.0)] and fasting plasma glucose similar [-1.3% (95% CI: -4.3, 1.7)] between obesity exposed and controls. After full adjustment (model 4) all results were similar with ONO vs. controls regarding all cardio-metabolic markers (data not shown).

## Discussion

We combined data from two longitudinal birth cohorts to study common cardio-metabolic markers in the adult offspring of mothers with GDM or overweight/obesity at start of pregnancy. There are two main findings in this study. First, maternal GDM was associated with increased insulin resistance and risk for an atherogenic lipid profile in adult offspring. Some, but not all, of this association was explained by confounding factors or current offspring characteristics including adiposity. Second, in offspring of mothers with pre-pregnancy overweight/obesity without GDM the consequences were not as clear. They had higher fasting glucose and insulin than controls, in part explained by parental and prenatal confounders or adult BMI or body fat percentage, but similar levels of other cardio-metabolic markers. This pattern differs from that of body composition. In this same cohort exposure to both maternal GDM and overweight/obesity was associated with higher offspring fat percentage and waist circumference, with stronger associations found related to maternal overweight/obesity (11).

Our findings of higher fasting glucose and insulin in OGDM compared with controls, attenuated to non-significance after adjusting for confounders and current characteristics. To further differentiate between the effects of maternal GDM and maternal overweight/obesity on offspring cardio-metabolic health, we divided OGDM participants into two subgroups based on maternal pre-pregnancy weight (BMI  $< 25\text{ kg/m}^2$  and BMI  $\geq 25\text{ kg/m}^2$ ). A combination of maternal GDM and overweight/obesity showed a greater effect on fasting glucose and insulin than maternal overweight/obesity alone. In the fully adjusted model, the adjustments attenuated these differences in fasting glucose and insulin; this attenuation was largely due to offspring BMI as a mediator in OGDM with maternal BMI  $\geq 25\text{ kg/m}^2$ .

Further, we report an atherogenic lipid profile in OGDM vs. controls, based on lower HDL-C and ApoA1 in OGDM. ApoA1 is a major component of HDL-C and low levels of ApoA1 are a well established risk factor of atherosclerosis.

In addition to the commonly measured indicators, we found lower SHBG in both OGDM-men and OGDM-women. SHBG is a measure of insulin resistance and hyperandrogenism, and this may reflect increased cardio-metabolic risk later in life.



Traditionally, the global obesity epidemic has been explained by an increase in availability and consumption of energy-dense foods and a simultaneous reduction in physical activity. However, other factors behind this rise in obesity prevalence exist, including genetic factors, an adverse intrauterine milieu and epigenetic changes this milieu may provoke (2). GDM is a common cause of such an adverse milieu and may cause epigenetic changes in offspring. For instance, in a GDM mice model, offspring exposed to GDM showed altered DNA methylation patterns in the pancreas, and this phenotype was characterized by dyslipidemia, insulin resistance and glucose intolerance (3). Our findings suggest that maternal GDM and pre-pregnancy overweight without diagnosed GDM may have distinct effects on offspring health. Previous studies have shown robust associations between higher maternal pre-pregnancy BMI and offspring adiposity as indicated by increased fat mass, fat-free mass and percentage of body fat in both neonates (8), and 6-7 year old children (9); higher BMI and greater waist circumference at adolescence (10), higher BMI, waist circumference, fat mass and fat percentage in young adulthood (11) and higher fat mass and BMI at older age (12). As for pre-pregnancy BMI and offspring cardio-metabolic risk factors, Gaillard et al reported an adverse cardio-metabolic profile (including lipid levels, glucose, insulin, homeostatic model assessment of insulin resistance) in 1392 adolescents at mean age 17 years (21). These associations were independent of maternal GDM and largely mediated by adolescent BMI. In another study, including 1400 participants at 32 years of age, higher maternal pre-pregnancy BMI was associated with higher offspring blood pressure, insulin and triglycerides and lower HDL-C (22), again independent of maternal GDM and fully explained by current BMI of the offspring. This is consistent with our finding of higher fasting glucose and insulin among ONO who, however, had similar serum lipids and other biomarkers as controls.

As to offspring of mothers with GDM, a previous study in 16-year-olds, in one of our source cohorts, showed that they have a higher BMI and waist circumference at adolescence than offspring of mothers without GDM (4). Further, in that study fasting insulin was higher and homeostatic model assessment-insulin sensitivity was lower in offspring to mothers with GDM, while blood lipids and glucose were similar to controls. To some extent maternal GDM is also associated with adult offspring body composition. In the same cohort participants, in which we now report on cardio-metabolic markers in the current study, higher fat percentages were seen in offspring exposed to GDM (11). As for maternal diabetes and offspring cardio-metabolic risk factors at adult age; recently a large Canadian cohort study including 467 850 mother-infant dyads, described an association between both maternal type 2 diabetes (T2D) during pregnancy and GDM with T2D in offspring by age 30 (23). In this study exposure to maternal T2D during pregnancy conferred a greater risk to offspring compared with GDM exposure (3.19 vs. 0.80 cases of T2D per 1000 person-years) (23). In line with the Canadian study, we also showed increased markers of insulin resistance, i.e. higher fasting insulin and lower SHBG, HDL-C and ApoA1, in offspring with prenatal exposure to maternal GDM as compared to controls.

Recently, Bellatorre et al reported an increase in liver fat, independent of offspring adiposity, in both childhood (mean age 10.4 years) and adolescence (mean age 16.4 years) in offspring of mothers with pre-pregnancy obesity ( $\text{BMI} \geq 30 \text{ kg/m}^2$ ), while no such effect was found in offspring of mothers with GDM (24). In our study we did not find any associations

between GDM or maternal pre-pregnancy overweight/obesity and biochemical markers of increased liver fat; levels of offspring liver enzymes were similar between groups.

Strengths of our study include a rather large sample size and long follow-up time. One of the indications for screening GDM was having a pre-pregnancy BMI  $\geq 25$  kg/m<sup>2</sup>, thus mothers with GDM could be reliably separated from our group of normoglycemic mothers with overweight/obesity. To further distinguish between the effects of maternal GDM and maternal overweight/obesity on offspring cardio-metabolic health, we reran all analyses with OGDM participants further divided into two subgroups based on maternal pre-pregnancy weight (BMI  $< 25$  kg/m<sup>2</sup> and BMI  $\geq 25$  kg/m<sup>2</sup> vs. controls). In these subgroup analyses with diminished numbers of participants, our results remained similar. Our participants come from an ethnically homogenous Finnish population, combined from two longitudinal study cohorts. The homogeneity of our study population may decrease the generalizability of our findings. Further, in the analyses we adjusted for important confounders, including perinatal and pregnancy related factors, parental hypertension, diabetes, stroke and myocardial infarction, and current participant related factors. However, residual confounding remains possible. Both treatment and GDM screening guidelines have changed during the previous 25 years. This may have introduced bias, depending on the adequacy of the screening. Thus, the GDM offspring in the current study may represent a more severe end of the GDM spectrum in today's pregnant women. Unfortunately, we do not have data on maternal glucose levels throughout pregnancy.

In sum, we found that maternal GDM is associated with increased levels of insulin resistance and a more atherogenic lipid profile in young adult offspring, as compared with controls. These findings suggest increased risk of cardio-metabolic diseases later in life. Maternal pre-pregnancy overweight or obesity alone was associated with offspring insulin resistance, but the association was weaker and explained by current adiposity.

**Statement of financial support:** The supporters of the study had no role in the study design; the collection, analysis, and interpretation of data; the writing of the report; and the decision to submit the paper for publication.

This study was supported by grants from the Academy of Finland (SALVE program for 2009–2012 and grants 127437, 129306, 130326, 134791, 263924 and 274794 to EK, JGE, KR and KH), Arvo and Lea Ylppö Foundation (to AL), Doctoral Programme for Public Health, University of Tampere (to MS), the Emil Aaltonen Foundation (to EK), European Commission (Framework 5 award QLG1-CT-2000-001643 to MRJ, H2020 award SC1-2016-RTD-733180 RECAP to EK), the Foundation for Pediatric Research (to EK, MT and AL), the Finnish Government Special Subsidiary for Health Sciences (evo) (to JGE), Finnish Medical Societies: Duodecim (to EK) and Finska Läkaresällskapet (to JGE, SA and NK), Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns minne (to NK), Svenska kulturfonden (to NK), the Jalmari and Rauha Ahokas Foundation (to EK), the Juho Vainio Foundation (to EK, MS, MT, MV and NK), the National Graduate School of Clinical Investigation (to MT), the Novo Nordisk Foundation (to EK and MV), the Signe and Ane Gyllenberg Foundation (to EK, JGE and NK), the Sigrid Jusélius Foundation (to EK), the Yrjö Jahnsson Foundation (EK, MS, NK and MV), the Bundesministerium für Forschung und Technik (Federal Government of Germany, Ministry of Science and Technology) program

grants PKE 4 and JUG 14 (FKZ's 0706224, 0706564, and 01EP9504) (to DW), Samfundet Folkhälsan (to JGE) and Päivikki and Sakari Sohlberg Foundation (to SA).

Academy of Finland, 127437, 129306, 130326, 134791, 263924 and 274794, Kajantie Eero; Academy of Finland <http://dx.doi.org/10.13039/501100002341>, 0, Johan G. Eriksson; Academy of Finland, Räikkönen Katri; Academy of Finland, 0, Heinonen Kati; Arvo and Lea Ylppö Foundation, 0, Lano Aulikki; Doctoral Programme for Public Health, University of Tampere, 0, Sipola Marika; Emil Aaltonen Foundation, 0, Kajantie Eero; European Commission, Framework 5 award QLG1-CT-2000-001643, Järvelin Marjo-Riitta; European Commission, H2020 award SC1-2016-RTD-733180, Kajantie Eero; Foundation for Pediatric Research, 0, Kajantie Eero; Foundation for Pediatric Research, 0, Tikanmäki Marjaana; Foundation for Pediatric Research, 0, Lano Aulikki; the Finnish Government Special Subsidiary for Health Sciences, 0, Johan G. Eriksson; Finnish Medical Societies: Duodecim, 0, Kajantie Eero; Finska Läkaresällskapet <http://dx.doi.org/10.13039/100010135>, 0, Johan G. Eriksson; Finska Läkaresällskapet <http://dx.doi.org/10.13039/100010135>, 0, Andersson Sture; Finska Läkaresällskapet <http://dx.doi.org/10.13039/100010135>, 0, Nina Kaseva; Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns Minne <http://dx.doi.org/10.13039/100010119>, 0, Nina Kaseva; Svenska Kulturfonden <http://dx.doi.org/10.13039/501100007247>, 0, Nina Kaseva; Jalmari and Rauha Ahokas Foundation, 0, Kajantie Eero; Juho Vainio Foundation, 0, Kajantie Eero; Juho Vainio Foundation, 0, Sipola Marika; Juho Vainio Foundation, 0, Tikanmäki Marjaana; Juho Vainio Foundation, 0, Vääräsmäki Marja; Juho Vainio Foundation, 0, Nina Kaseva; National Graduate School of Clinical Investigation, 0, Tikanmäki Marjaana; Novo Nordisk Foundation, 0, Kajantie Eero; Novo Nordisk Foundation, 0, Vääräsmäki Marja; Signe and Ane Gyllenberg Foundation, 0, Kajantie Eero; Signe and Ane Gyllenberg Foundation, 0, Johan G. Eriksson; Signe and Ane Gyllenberg Foundation, 0, Nina Kaseva; Sigrid Jusélius Foundation, 0, Kajantie Eero; Yrjö Jahnsson Foundation, 0, Kajantie Eero; Yrjö Jahnsson Foundation, 0, Sipola Marika; Yrjö Jahnsson Foundation, 0, Nina Kaseva; Yrjö Jahnsson Foundation, 0, Vääräsmäki Marja; Bundesministerium für Forschung und Technik (Federal Government of Germany, Ministry of Science and Technology, grants PKE 4 and JUG 14 (FKZ's 0706224, 0706564, and 01EP9504), Wolke Dieter; Samfundet Folkhälsan <http://dx.doi.org/10.13039/501100004810>, 0, Johan G. Eriksson; Päivikki and Sakari Sohlberg Foundation, 0, Andersson Sture

**Correspondence and reprint requests:** Nina Kaseva, National Institute for Health and Welfare, Public Health Solutions, Public Health Promotion Unit, P.O. Box 30, 00271 Helsinki, Finland. Phone: +358 400 837526, Fax +358 29 524 8338. E-mail address: [nina.kaseva@fimnet.fimailto](mailto:nina.kaseva@fimnet.fimailto):

Disclosure summary:

I certify that neither I nor my co-authors have a conflict of interest that is relevant to the subject matter or materials included in this work.

## References

1. Bateson P, Barker D, Clutton-Brock T, Deb D, D'Udine B, Foley RA, Gluckman P, Godfrey K, Kirkwood T, Lahr MM, McNamara J, Metcalfe NB, Monaghan P, Spencer HG, Sultan SE 2004 Developmental plasticity and human health. *Nature* 430(6998):419-421
2. van Dijk SJ, Molloy PL, Varinli H, Morrison JL, Muhlhausler BS, Members of EpiSCOPE 2015 Epigenetics and human obesity. *Int J Obes (Lond)* 39(1):85-97
3. Zhu Z, Chen X, Xiao Y, Wen J, Chen J, Wang K, Chen G 2019 Gestational diabetes mellitus alters DNA methylation profiles in pancreas of the offspring mice. *J Diabetes Complications* 33(1):15-22
4. Väärasmäki M, Pouta A, Elliot P, Tapanainen P, Sovio U, Ruokonen A, Hartikainen AL, McCarthy M, Järvelin MR 2009 Adolescent manifestations of metabolic syndrome among children born to women with gestational diabetes in a general-population birth cohort. *Am J Epidemiol* 169(10):1209-1215
5. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, Schmidt L, Damm P 2009 Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. *J Clin Endocrinol Metab* 94(7):2464-2470
6. Drake AJ, Reynolds RM 2010 Impact of maternal obesity on offspring obesity and cardiometabolic disease risk. *Reproduction* 140(3):387-398
7. Nicholas LM, Morrison JL, Rattanatray L, Zhang S, Ozanne SE, McMillen IC 2016 The early origins of obesity and insulin resistance: Timing, programming and mechanisms. *Int J Obes (Lond)* 40(2):229-238
8. Starling AP, Brinton JT, Glueck DH, Shapiro AL, Harrod CS, Lynch AM, Siega-Riz AM, Dabelea D 2015 Associations of maternal BMI and gestational weight gain with neonatal adiposity in the healthy start study. *Am J Clin Nutr* 101(2):302-309
9. Castillo H, Santos IS, Matijasevich A 2015 Relationship between maternal pre-pregnancy body mass index, gestational weight gain and childhood fatness at 6-7 years by air displacement plethysmography. *Matern Child Nutr* 11(4):606-617
10. Pirkola J, Pouta A, Bloigu A, Hartikainen AL, Laitinen J, Järvelin MR, Väärasmäki M 2010 Risks of overweight and abdominal obesity at age 16 years associated with prenatal exposures to maternal prepregnancy overweight and gestational diabetes mellitus. *Diabetes Care* 33(5):1115-1121
11. Kaseva N, Väärasmäki M, Matinelli HM, Sipola-Leppänen M, Tikanmäki M, Heinonen K, Lano A, Wolke D, Andersson S, Järvelin MR, Räikkönen K, Eriksson JG, Kajantie E 2018 Pre-pregnancy overweight or obesity and gestational diabetes as predictors of body composition in offspring twenty years later: Evidence from two birth cohort studies. *Int J Obes (Lond)* 42(4):872-879
12. Eriksson JG, Sandboge S, Salonen M, Kajantie E, Osmond C 2015 Maternal weight in pregnancy and offspring body composition in late adulthood: Findings from the Helsinki birth cohort study (HBCS). *Ann Med* 47(2):94-99
13. Sipola-Leppänen M, Väärasmäki M, Tikanmäki M, Matinelli HM, Miettola S, Hovi P, Wehkalampi K, Ruokonen A, Sundvall J, Pouta A, Eriksson JG, Järvelin MR, Kajantie E 2015 Cardiometabolic risk factors in young adults who were born preterm. *Am J Epidemiol* 181(11):861-873
14. Järvelin MR, Hartikainen-Sorri AL, Rantakallio P 1993 Labour induction policy in hospitals of different levels of specialisation. *Br J Obstet Gynaecol* 100(4):310-315

15. Tikanmäki M 2018 Preterm birth and parental and pregnancy related factors in association with physical activity and fitness in adolescence and young adulthood. Figure 7, p 83. Oulu: Oulu University
16. Heinonen K, Räikkönen K, Pesonen AK, Kajantie E, Andersson S, Eriksson JG, Niemelä A, Vartia T, Peltola J, Lano A 2008 Prenatal and postnatal growth and cognitive abilities at 56 months of age: A longitudinal study of infants born at term. *Pediatrics* 121(5):e1325-33
17. Wolke D, Sohne B, Riegel K, Ohrt B, Österlund K 1998 An epidemiologic longitudinal study of sleeping problems and feeding experience of preterm and term children in southern Finland: Comparison with a southern German population sample. *J Pediatr* 133(2):224-231
18. Miettola S, Hartikainen AL, Väärasmäki M, Bloigu A, Ruokonen A, Järvelin MR, Pouta A 2013 Offspring's blood pressure and metabolic phenotype after exposure to gestational hypertension in utero. *Eur J Epidemiol* 28(1):87-98
19. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva A, Hod M, Kitzmiller JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI 2010 International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 33(3):676-682
20. Kaseva N, Väärasmäki M, Sundvall J, Matinoli HM, Sipola M, Tikanmäki M, Heinonen K, Lano A, Wehkalampi K, Wolke D, Ruokonen A, Andersson S, Järvelin MR, Räikkönen K, Eriksson JG, Kajantie E. Data from: Gestational diabetes, but not pre-pregnancy overweight predicts cardio-metabolic markers in offspring twenty years later. *JULKARI/THL Repository*. Deposited 5 February 2019: <http://urn.fi/URN:NBN:fi-fe201902054087>
21. Gaillard R, Welten M, Oddy WH, Beilin LJ, Mori TA, Jaddoe VW, Huang RC 2016 Associations of maternal prepregnancy body mass index and gestational weight gain with cardio-metabolic risk factors in adolescent offspring: A prospective cohort study. *BJOG* 123(2):207-216
22. Hochner H, Friedlander Y, Calderon-Margalit R, Meiner V, Sagy Y, Avgil-Tsadok M, Burger A, Savitsky B, Siscovick DS, Manor O 2012 Associations of maternal prepregnancy body mass index and gestational weight gain with adult offspring cardiometabolic risk factors: The Jerusalem perinatal family follow-up study. *Circulation* 125(11):1381-1389
23. Wicklow BA, Sellers EAC, Sharma AK, Kroeker K, Nickel NC, Philips-Beck W, Shen GX 2018 Association of gestational diabetes and type 2 diabetes exposure in utero with the development of type 2 diabetes in first nations and non-first nations offspring. *JAMA Pediatr*
24. Bellatorre A, Scherzinger A, Stamm E, Martinez M, Ringham B, Dabelea D 2018 Fetal overnutrition and adolescent hepatic fat fraction: The exploring perinatal outcomes in children study. *J Pediatr* 192:165-170.e1

Figure 1. Flow chart of the study population, including participants from two birth cohort studies.

**Table 1.** Baseline participant characteristics of adult offspring, exposed to maternal gestational diabetes (regardless of maternal BMI), maternal pre-pregnancy obesity or overweight but not gestational diabetes and their controls, i.e. offspring of normoglycemic mothers with normal pre-pregnancy weight.

Characteristic	Gestational	P value <sup>b</sup>	Pre-	P value <sup>b</sup>	Control
----------------	-------------	----------------------	------	----------------------	---------

	diabetes (n=193)		pregnancy obesity or overweight <sup>a</sup> , no gestational diabetes (n= 157)		n=556
<i>Birth/Perinatal characteristics</i>					
Maternal body mass index before pregnancy, mean (SD), kg/m <sup>2</sup>	24.9 (5.4)	<0.001	28.0 (3.0)	<0.001	21.2 (1.9)
Twin pregnancy, n (%)	2 (1.3)		2 (1.3)		8 (1.4)
Maternal hypertension, n (%)	52 (26.9)	<0.001	53 (33.8)	<0.001	73 (13.1)
Maternal pre-eclampsia, n (%)	12 (6.2)		8 (5.1)		17 (3.1)
Maternal smoking during pregnancy, n (%)	23 (11.9)		33 (21.0)		90 (16.2)
Birth weight, mean (SD), g	3687 (626)	<0.01	3458 (864)		3535 (465)
Birth weight SD score, mean (SD)	0.55 (1.2)	<0.001	0.09 (1.4)		-0.05 (0.9)
Gestational age, mean (SD), weeks	39.0 (0.2)	<0.001	39.1 (2.9)	<0.001	39.9 (1.4)
Small for gestational age, n (%)	1 (0.5)		15 (9.6)	<0.001	8 (1.4)
Large for gestational age, n (%)	26 (13.5)	<0.001	10 (6.4)	<0.01	10 (1.8)
Male, n (%)	105 (54.4)	<0.05	78 (49.7)		258 (46.4)
<i>Current characteristics</i>					
Age, mean (SD), years	23.4 (1.3)	<0.001	24.8 (1.1)		24.4 (1.3)
Daily smoking, n (%)	55 (28.5)	<0.05	52 (33.1)		141 (25.4)
Body mass index, mean (SD), kg/m <sup>2</sup>					
Men	25.6 (4.7)	<0.001	26.5 (4.8)	<0.001	24.0 (3.6)
Women	24.3 (4.4)	<0.05	24.7 (4.6)	<0.01	23.0 (4.2)
Body mass index $\geq$ 25kg/m <sup>2</sup> , n (%)	81 (42.0)	<0.01	78 (49.7)	<0.001	158 (28.4)
Body mass index $\geq$ 30kg/m <sup>2</sup> , n (%)	24 (12.4)	<0.05	22 (14.0)	<0.05	41 (7.4)
Height, mean (SD), cm					
Men	178.9 (7.0)		178.0 (6.7)		178.9 (7.0)
Women	165.9 (6.3)		164.7 (6.4)		165.2 (6.2)
Parental education, n (%)		<0.05		<0.001	
Basic	28 (14.5)		21 (13.3)		30 (5.4)
Secondary	101 (52.3)		83 (52.9)		281 (50.5)
Lower-level tertiary	16 (8.3)		18 (11.5)		66 (11.9)
Upper-level tertiary	46 (23.8)		28 (17.8)		165 (29.7)
Maternal medical conditions at offspring mean age 24 years, n (%)					
Hypertension	42 (21.8)	<0.001	50 (31.8)	<0.001	52 (9.4)
Diabetes	70 (36.3)	<0.001	18 (11.5)	<0.001	10 (1.8)
Stroke or myocardial infarction	3 (1.6)		1 (0.6)		3 (0.5)
Paternal medical conditions at offspring mean age 24 years, n (%)					
Hypertension	40 (20.1)		28 (17.8)		83 (14.9)
Diabetes	16 (8.3)		23 (14.6)		43 (7.7)
Stroke or myocardial infarction	13 (6.7)		3 (1.9)		19 (3.4)

<sup>a</sup> Pre-pregnancy body mass index  $\geq$  25kg/m<sup>2</sup>

<sup>b</sup> Linear regression model, adjusted for age, sex and source cohort, comparing offspring exposed to maternal gestational diabetes or maternal pre-pregnancy overweight/obesity with controls. All remaining p values are  $>$ 0.05.

**Table 2.** Cardio-metabolic markers of adult offspring, exposed to maternal gestational diabetes (regardless of maternal BMI), maternal pre-pregnancy obesity or overweight but not gestational diabetes and their controls, i.e. offspring of normoglycemic mothers with normal pre-pregnancy weight.

Characteristic	Gestational diabetes (n=193)	Pre-pregnancy obesity or overweight, no gestational diabetes	Control (n=556)	Reference

		(n= 157)		
Fasting plasma glucose, mean (SD), mmol/l	5.2 (1.1)	5.2 (1.2)	5.1 (1.1)	4.2-6.0
Fasting serum insulin, mean (SD), mU/l	10.3 (2.1)	22.8 (2.5)	14.8 (2.6)	2.0-20
Total cholesterol, mean (SD), mmol/l	4.5 (1.2)	4.7 (1.2)	4.6 (1.2)	< 5.0
HDL cholesterol, mean (SD), mmol/l	1.4 (1.3)	1.5 (1.3)	1.6 (1.3)	> 1.0 / > 1.2 <sup>a</sup>
LDL cholesterol, mean (SD), mmol/l	2.7 (1.4)	2.7 (1.3)	2.6 (1.3)	< 3.0
Triglycerides, mean (SD), mmol/l	1.0 (1.6)	1.0 (1.6)	0.9 (1.6)	< 1.7
Lipoprotein (a), mean (SD), mg/l	78.8 (3.1)	99.0 (3.3)	95.1 (3.1)	< 250
Apolipoprotein A1, mean (SD), g/l	1.4 (1.2)	1.5 (1.2)	1.5 (1.2)	1.0-2.0 / 1.1-2.3 <sup>a</sup>
Apolipoprotein B, mean (SD) g/l	0.7 (1.3)	0.8 (1.3)	0.7 (1.3)	0.66-1.33 / 0.60-1.17 <sup>a</sup>
Serum free fatty acid, mean, (SD), mmol/l	0.5 (1.6)	0.5 (1.5)	0.5 (1.6)	0.08-0.7
Serum sex hormone binding globulin, (SD) nmol/l				
Men	28.6 (1.5)	31.0 (1.5)	32.4 (1.5)	14-71
Women	100.2 (2.4)	126.1 (2.6)	137.3 (2.3)	20-155
Serum testosterone, (SD), nmol/l				
Men	18.4 (1.4)	17.6 (1.6)	19.7 (1.4)	10-38
Women	1.3 (1.4)	1.3 (1.4)	1.3 (1.4)	0.4-2
Plasma uric acid, mean (SD), µmol/l	290.1 (1.6)	286.4 (1.3)	279.7 (1.3)	230-480 / 155-400 <sup>a</sup>
High-sensitivity C-reactive protein, mean (SD), mg/l	1.0 (3.5)	1.2 (3.3)	1.0 (3.7)	0.2-3
Plasma alanine aminotransferase, mean (SD), U/l	23.0 (1.7)	21.9 (1.8)	21.1 (1.7)	< 50 / < 35 <sup>a</sup>
Plasma aspartate transaminase, mean (SD), U/l	22.5 (1.4)	24.7 (1.4)	23.3 (1.4)	15-45 / 15-35 <sup>a</sup>
Plasma gamma glutamate, mean (SD), U/l	19.2 (1.8)	20.2 (1.8)	18.0 (1.7)	< 60 / < 40 <sup>a</sup>
Systolic blood pressure, mean (SD), mmHg	119.4 (14.3)	126.2 (16.4)	122.6 (15.0)	<130
Diastolic blood pressure, mean (SD), mmHg	75.1 (7.5)	76.8 (8.9)	76.0 (8.1)	<85
Heart rate, mean (SD), beats/min	71.0 (13.0)	74.2 (14.0)	72.7 (12.1)	60-80

Means other than blood pressure and pulse are geometric means. The geometric mean is the  $n^{\text{th}}$  root of the product of  $n$  values. Geometric standard deviations correspond to the percentage increase in a variable corresponding to one standard deviation unit change in the logarithm of the variable.

Statistical comparisons among the three groups are shown in Table 3.

<sup>a</sup> men/women

**Table 3.** Cardio-metabolic markers of young adults born to mothers with gestational diabetes (regardless of maternal BMI) compared with controls, comprising offspring of normoglycemic mothers with normal pre-pregnancy weight, and offspring of mothers with pre-pregnancy obesity or overweight but no gestational diabetes, compared with controls.

Characteristic/Measure and model	Controls (n=556)	Maternal gestational diabetes (n=193)			Maternal pre-pregnancy obesity or overweight, no gestational diabetes (n=157)		
	Mean (SD)	Mean difference <sup>a</sup>	95 % Confidence interval	P value	Mean difference <sup>a</sup>	95 % Confidence interval	P value
Fasting plasma glucose, mmol/l	5.1 (1.1)						
1		1.6	0.1, 3.1	0.03	2.3	0.5, 4.3	0.01
4		0.4	-1.3, 2.2	0.62	0.4	-1.5, 2.3	0.69
Fasting serum insulin, mU/l	14.8 (2.6)						

1		12.7	4.4, 21.9	0.002	8.7	0.2, 17.8	0.05
4		8.4	-0.1, 17.6	0.05	-3.1	-10.7, 5.0	0.44
Serum testosterone in men, nmol/l	19.7 (1.4)						
1		-7.9	-15.2, 0.2	0.06	-10.1	-18.4, -0.9	0.03
4		-7.3	-15.9, 2.1	0.12	-6.1	-15.4, 4.2	0.23
Serum testosterone in women, nmol/l	1.3 (1.4)						
1		0.2	-8.6, 9.7	0.97	1.0	-7.7, 10.6	0.83
4		3.8	-7.0, 15.8	0.51	0.5	-9.4, 11.5	0.92
Serum sex hormone binding globulin in men, nmol/l	32.4 (1.5)						
1		-12.4	-20.2, -3.9	0.005	-3.9	-13.3, 6.5	0.45
4		-10.3	-19.2, -0.5	0.04	2.7	-7.9, 14.6	0.63
Serum sex hormone binding globulin in women, nmol/l	137.3 (2.3)						
1		-33.2	-46.3, -16.8	0.0003	-3.3	-22.3, 20.3	0.76
4		-36.6	-50.9, -18.0	0.001	2.0	-20.4, 30.6	0.88
Serum free fatty acid, mmol/l	0.5 (1.6)						
1		-3.6	-11.0, 4.5	0.37	3.9	-4.1, 12.6	0.35
4		-6.9	-15.5, 2.5	0.15	2.2	-6.7, 12.0	0.64
Total cholesterol, mmol/l	4.6 (1.2)						
1		-2.9	-6.5, 0.9	0.14	1.9	-3.9, 8.1	0.53
4		-3.9	-7.5, -0.2	0.04	-0.3	-4.0, 3.6	0.88
HDL cholesterol, mmol/l	1.6 (1.3)						
1		-6.6	-10.9, -2.2	0.004	-0.6	-7.3, 6.5	0.86
4		-5.4	-9.4, -1.0	0.02	-1.8	-5.8, 2.4	0.40
LDL cholesterol, mmol/l	2.6 (1.3)						
1		-1.4	-7.5, 5.2	0.67	2.6	-6.9, 13.1	0.59
4		-4.0	-9.8, 2.0	0.19	0.2	-5.5, 6.3	0.95
Triglycerides, mmol/l	0.9 (1.6)						
1		5.5	-3.7, 15.8	0.25	6.5	-7.1, 22.1	0.36
4		0.0	-8.8, 9.6	0.98	-1.0	-9.6, 8.3	0.82
Lipoprotein (a) mg/l	95.1 (3.1)						
1		-18.9	-33.9, -0.4	0.05	4.3	-16.1, 29.4	0.70
4		-10.1	-30.0, 15.5	0.40	6.3	-17.1, 36.3	0.63
Apolipoprotein A1, g/l	1.5 (1.2)						
1		-4.5	-7.5, -1.4	0.005	-2.7	-5.6, 0.4	0.09
4		-4.6	-8.1, -1.0	0.01	-2.0	-5.2, 1.4	0.25
Apolipoprotein B, g/l	0.7 (1.3)						
1		-1.6	-6.1, 3.1	0.50	-0.1	-2.3, 2.1	0.91
4		-4.5	-9.5, 0.9	0.10	0.3	-4.6, 5.4	0.91
Plasma uric acid, $\mu$ mol/l	279.7 (1.3)						
1		4.5	-2.8, 12.2	0.23	2.9	-1.9, 8.0	0.23
4		-2.9	-8.4, 3.1	0.35	-2.8	-6.7, 1.2	0.17
High-sensitivity C-reactive protein, mg/l	1.0 (3.7)						
1		-14.6	-33.6, 9.7	0.22	-4.3	-33.9, 38.7	0.82
4		-17.0	-35.8, 7.4	0.16	16.4	-8.7, 48.6	0.22
Plasma alanine aminotransferase, U/l	21.1 (1.7)						
1		4.5	-4.9, 14.8	0.36	13.2	-2.0, 30.7	0.09
4		-1.7	-10.4, 8.0	0.72	-1.9	-10.6, 7.8	0.70
Plasma aspartate transaminase, U/l	23.3 (1.4)						
1		1.9	-4.9, 9.3	0.60	3.9	-7.0, 16.2	0.50
4		1.6	-5.0, 8.7	0.64	0.2	-6.2, 7.0	0.95
Plasma gamma glutamate, U/l	18.0 (1.7)						
1		4.9	-4.6, 15.4	0.32	7.8	-6.2, 24.0	0.29
4		-1.3	-10.5, 8.9	0.79	-0.3	-9.2, 9.6	0.96
Systolic blood pressure, mmHg <sup>a</sup>	122.6 (15.0)						
1		-0.9	-2.7, 1.0	0.36	0.0	-2.0, 2.0	1.0
4		-3.6	-5.7, -1.5	0.001	-3.5	-5.7, -1.4	0.001
Diastolic blood pressure, mmHg <sup>a</sup>	76.0 (8.1)						



1		-0.9	-2.2, 0.5	0.21	0.4	-1.0, 1.9	0.61
4		-2.2	-3.8, -0.7	0.006	-1.6	-3.2, 0.0	0.05
Heart rate, beats/min <sup>a</sup>	72.7 (12.1)						
1		-1.2	-3.3, 0.9	0.27	1.4	-0.8, 3.6	0.21
4		-1.0	-3.5, 1.5	0.41	1.1	-1.5, 3.6	0.41

<sup>a</sup> Mean differences for blood pressures are expressed as mmHg, and for heart rate as beats/min while the remaining results are presented as % difference.

Multiple linear regression models as follows:

Model 1 adjusted for age, sex and source cohort

Model 4 adjusted for age, sex, source cohort, gestational age, birth weight standard deviation score, maternal hypertension or preeclampsia during pregnancy, maternal smoking during pregnancy, parental educational attainment and parental hypertension, diabetes, stroke or myocardial infarction, body mass index, height and daily smoking

Models 2 and 3 are shown in Supplementary Table 3.

ADVANCE ARTICLE

